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Abstract
Lanthanide complexes (Eu3+, Gd3+ and Yb3+) of two different 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid tetraamide derivatives containing two (2) and four
(3) O-benzyl-L-serine amide substituents were synthesized and their chemical exchange saturation
transfer (CEST) and relaxometric properties were examined in the presence and absence of human
serum albumin (HSA). Both Eu2 and Eu3 display a significant CEST effect from a single slowly
exchanging Eu3+-bound water molecule, making these PARACEST complexes potentially useful as
vascular MRI agents. Yb2 also showed a detectable CEST effect from both the Yb3+-bound water
protons and the exchangeable NH amide protons, making it potentially useful as a vascular pH sensor.
Fluorescence displacement studies using reporter molecules indicate that both Gd2 and Gd3 displace
© SBIC 2007
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dansylsarcosine from site II of HSA with inhibition constants of 32 and 96 µM, respectively, but
neither complex significantly displaces warfarin from site I. Water proton relaxation enhancements
of 135 and 171% were observed upon binding of Gd2 and Gd3 to HSA, respectively, at 298 K and
pH 7.4.

Keywords
Chemical exchange saturation transfer agents; MRI contrast; Albumin binding; Paramagnetic
relaxation

Introduction
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Magnetic resonance imaging (MRI) is one of the most powerful and versatile tools in
biomedicine, providing not only high-resolution anatomical images but also functional data
such as blood flow, tissue perfusion, and distribution of metabolites. MRI detects mostly tissue
water and fat and does not require injection of exogenous agents to produce image contrast.
Nevertheless, paramagnetic contrast agents (CAs) are often used to selectively alter tissue
contrast by altering the relaxation rate of tissue water. Current diagnostic CAs for MRI are
largely based on paramagnetic gadolinium complexes [1,2] that highlight only those tissue
regions where an agent accumulates for a period of time that is abnormal compared with that
for well-vascularized tissue. Accumulation of a Gd3+-based agent results in a shortening of the
bulk water spin-lattice relaxation time (T1) and hence brightening of the image in that region.
Although current nonspecific, extracellular Gd3+-based agents are widely accepted and used
clinically, interest in “smart” or “responsive” agents that can provide additional physiological
or metabolic information to aid in a clinical diagnosis is growing.
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Recently a new class of CA based upon a chemical exchange saturation transfer (CEST)
mechanism have been proposed and demonstrated. Unlike other image-darkening agents that
function by shortening the transverse relaxation time (T2) of water protons, CEST agents act
by decreasing the water signal intensity via chemical exchange of saturated spins. This
approach was first demonstrated by Ward and Balaban [3] using low molecular weight
diamagnetic molecules containing exchangeable OH or NH groups. They showed that
magnetic resonance contrast can be switched on/off by applying a saturating irradiation pulse
and, since chemical exchange between such groups and bulk water is pH dependent, such
systems can potentially be used to image tissue pH [3,4]. One disadvantage of such diamagnetic
agents is that the chemical shift difference between exchanging OH and NH protons and bulk
water is typically quite small, often less than 5 ppm. This makes it difficult to selectively
activate the CEST agent in tissues where the bulk water signal can be rather broad.
Nevertheless, Geoffeney et al. [5], Snoussi et al. [6], and Zhou et al. [7] have shown that CEST
can be amplified by using endogenous and exogenous macromolecules with large numbers of
exchanging sites or endogenous proteins or peptides. We recently reported that the weakly
paramagnetic Eu1 (Structure 1) has a Eu3+-bound water resonance near 50 ppm that can be
used as an RF antenna to initiate CEST. Protons on this bound water molecule also have a
compared with diamagnetic NH or OH protons,
much shorter exchange lifetime
a feature that can potentially enhance CEST contrast at equivalent agent concentrations [8,9].
Since that early report, several other papers have appeared on responsive paramagnetic CEST
agents capable of sensing physiological indices such as pH [10–12], lactate [13], glucose
[14], and temperature [4,15].
Just as one might amplify the effect of a Gd3+-based T1 agent by conjugation to a higher
molecular weight macromolecule such as albumin, polylysine, or a dendrimer, one could also
conjugate multiple PARACEST agents to a polymer backbone to decrease the “effective”
J Biol Inorg Chem. Author manuscript; available in PMC 2009 October 9.
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concentration of the agent. Since the CEST efficiency of such agents is highly dependent upon
the rate of water exchange, one question of interest is whether interactions between a
PARACEST agent and protein surface residues for example might either enhance or quench
the CEST effect. To test this hypothesis, we prepared and characterized PARACEST agents
containing two (Ln2) or four (Ln3) O-benzyl functionalities, groups known to impart a high
binding affinity for albumin [16,17] (Structure 1). The albumin-binding properties of these
agents were measured using fluorescence spectroscopy and their CEST behavior in the
presence and absence of albumin was measured to determine whether water or proton exchange
was altered upon binding of the agent to albumin.

Materials and methods
General remarks
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All reagents and solvents were purchased from commercially available sources and used as
received. 1H, CEST and 13C spectra were recorded with a JEOL Eclipse 270 spectrometer or
a Varian INOVA-400 spectrometer operating at 270 and 67.5 MHz or 400 and 100 MHz,
respectively. Water proton relaxation measurements were made using an inversion-recovery
pulse sequence with a MRS-6 NMR analyzer (Institut “Jožef Stefan,” Ljubljana, Slovenia)
operating at 20 MHz. IR spectra were recorded using a PerkinElmer 1600 Fourier transform
IR spectrophotometer. Melting points were determined with a Fisher–Johns melting point
apparatus and are uncorrected.
1,7-Dibenzyloxycarbonyl-1,4,7,10-tetraazacyclododecane was prepared according to
previously published methods [18].
2-(2-Bromoacetamido)-3-(benzyloxy)propanoic acid

NIH-PA Author Manuscript

A solution of bromoacetyl bromide (12.9 g; 64.0 mmol) in CH2Cl2 (20 mL) was added
dropwise to a solution of 2-amino-3-(benzyloxy)propanoic acid (5.0 g, 25.6 mmol) and
potassium carbonate (14.2 g, 102.4 mmol) in aqueous 2 N NaOH (12 mL) at 273 K. The reaction
mixture was stirred at 273 K for 10 min before warming it to room temperature and stirring
for a further 2 h. The two layers were separated, and the pH of the aqueous layer was adjusted
to between 1 and 2 with 20% hydrochloric acid. The aqueous phase was then extracted with
CH2Cl2 (200 mL). The organic extracts were washed with water (2 × 100 mL), dried
(Na2SO4), and the solvents were removed under reduced pressure to afford 2-(2bromoacetamido)-3-(benzyloxy)propanoic acid (4) as a colorless gum (5.70 g, 70%). 1H NMR
(400 MHz, CDCl3, δ): 10.38 (1H, s br, COOH), 7.26 (5H, m, Ar), 4.68 (1H, m, NCHCO), 4.53
(1H, d aa′ system, 2JH–H = 12 Hz, OCH2Ar), 4.47 (1H, d aa′ system, 2JH–H = 12 Hz,OCH2Ar),
4.04–3.44 (4H, m, CHCH2O, COCH2Br). 13C NMR (100 MHz, CDCl3, δ): 173.6 (NCO2),
166.9 (NHC=O), 137.3 (Ar), 128.8 (Ar), 128.3 (Ar), 128.0 (Ar), 73.6 (OCH2Ar), 69.1
(CHCH2O), 53.5 (CH), 28.7 (COCH2Br); νmax (cm−1): 3,379 (br, OH), 2,969, 2,938, 2,866,
1,733 (C=O); 1,652 (C=O), 1,538, 1,454, 1,396, 1,361, 1,206, 1,105, 1,048. m/z (ESMS, ESI–):
316 (100%, [M – H]−); an appropriate bromine isotope pattern was observed.
tert-Butyl 2-(2-bromoacetamido)-3-(benzyloxy)propanoate
To a solution of the acid 4 (5.5 g, 17.5 mmol) in tetrahydrofuran (THF; 150 mL) cooled in an
ice bath was slowly added tert-butyl trichloroacetimidate (9.6 g, 43.8 mmol) in THF (50 mL).
After addition was complete, BF3·OEt2 (0.66 mL, 5.3 mmol) was also added very slowly. The
reaction mixture was allowed to warm to room temperature and stirred for 12 h. The resulting
solution was diluted with diethyl ether (200 mL) and washed with saturated aqueous
NaHCO3 (2 × 60 mL), water (2 × 80 mL), and dried (Na2SO4). The solvents were removed in
vacuo and the residue suspended in CH2Cl2 (30 mL). The suspension was cooled to 273 K and
allowed to stand for 1 h. The solids were removed by filtration and the solvents were removed
J Biol Inorg Chem. Author manuscript; available in PMC 2009 October 9.
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in vacuo. The oily residue was purified by column chromatography over silica gel eluting with
5% CH3OH in CH2Cl2 to afford tert-butyl 2-(2-bromoacetamido)-3-(benzyloxy)propanoate
(5) as a colorless oil (3.7 g, 56%). Rf = 0.71 (SiO2, 5% CH3 OH in CH2Cl2). 1H NMR (400
MHz, CDCl3, δ): 7.25 (5H, m, Ar), 4.54 (1H, m, NHCHCH2), 4.51 (1H, d aa′ system, 2JH–H
= 12 Hz, OCH2Ar), 4.44 (1H, d aa′ system, 2JH–H = 12 Hz, OCH2Ar), 3.90–3.47 (4H, m,
CHCH2O, COCH2Br), 1.41 (9H, s, C(CH3)3). 13C NMR (100 MHz, CDCl3, δ): 169.2 (CO2),
166.1 (NHC=O), 138.1 (Ar), 129.0 (Ar), 128.4 (Ar), 128.3 (Ar), 83.2 [C(CH3)3], 73.9
(OCH2Ar), 70.2 (CHCH2O), 54.4 (NHCHCH2), 29.4 (COCH2Br), 28.6 [C(CH3)3]. νmax
(cm−1): 2,974, 2,920, 2,862, 1,734 (C=O), 1,652 (C=O), 1,539, 1,520, 1,506, 1,455, 1,393,
1,367, 1,242, 1,149, 1,104, 1,032. m/z (ESMS, ESI–): 370 (100%, [M – H]−); an appropriate
bromine isotope pattern was observed.
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra-(2-(methylene benzyloxy ether)-tert-butyl
acetate) acetamide

NIH-PA Author Manuscript

The bromoacetamide 5 (1.4 g, 4.1 mmol), cyclen (170 mg, 0.96 mmol), and N,Ndiisopropylethylamine (0.9 g, 7.0 mmol) were dissolved in CH3CN (30 mL). The resulting
solution was heated with stirring at 328 K for 3 days. The reaction mixture was then cooled to
room temperature and the solvents removed in vacuo. The oily residue was taken up in
CHCl3 (200 mL) and washed with water (2 × 75 mL). The organic layer was dried (Na2SO4)
and solvents were removed under reduced pressure. The oily residue was then titrated with
diethyl ether to afford 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-(2-(methylene
benzyloxy ether)-tert-butyl acetate) acetamide (6) as a colorless gum (1.1 g, 93%). 1H NMR
(270 MHz, CDCl3, δ): 7.25 (24H, m, Ar and NH), 4.65 (4H, m, CH), 4.54 (4H, q aa′
system, 2JH–H = 12 Hz, CH2Ar), 4.52 (4H, q aa′ system, 2JH–H = 12 Hz, CH2Ar), 3.85 (8H,
m, CHCH2), 3.70 (8H, s br, NCH2CO), 3.50-2.80 (16H, m br, NCH2 ring), 1.20 [36H, s, C
(CH3)]. 13C NMR (68 MHz, CDCl3, δ): 170.0 (C=O), 169.2 (C=O), 137.7 (Ar), 128.5 (Ar),
128.0 (Ar), 127.9 (Ar), 73.31 [C(CH3)3], 69.2, (OCH2Ar), 57.1 (CHCH2), 53.0 (NCH2 ring),
52.2 (CH), 51.1 (NCH2O), 14.2 [C(CH3)3]. m/z (ESMS ESI+): 1,224 (100%, [M + H]+).
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra-[2-(methylene benzyloxy ether)-acetic acid]
acetamide

NIH-PA Author Manuscript

The tert-butyl ester 6 (1.0 g, 0.72 mmol) was dissolved in 50% trifluoroacetic acid (TFA) in
CH2Cl2 (10 mL). The resulting solution was stirred at room temperature for 5 h. The solvents
were removed under vacuum and dichloromethane (20 mL) was added to the residue. The
solvents were again removed under reduced pressure and this procedure was repeated a total
of three times. After drying under high vacuum, 1,4,7,10-tetraazacyclododecane-1,4,7,10tetra-[2-(methylene benzyloxy ether)-acetic acid] acetamide (3) was obtained as a colorless
gum (0.55 g, 69%). 1H NMR (270 MHz, CD3OD, δ): 7.28 (5H, m, Ar), 4.63 (4H, m, CH), 4.59
(4H, q aa′ system, 2JH–H = 12 Hz, CH2Ar), 4.47 (4H, q aa′ system, 2JH–H = 12 Hz, CH2Ar),
3.82 (8H, m, CHCH2), 3.72 (8H, s, OCH2N), 3.32-3.21 (16H, m br, NCH2 ring). 13C NMR
(68 MHz, CD3OD, δ): 172.0 (C=O), 169.2 (C=O), 137.9 (Ar), 128.2 (Ar), 127.8 (Ar), 127.7
(Ar), 73.0 (CHCH2), 69.4 (OCH2Ar), 53.3 (CH2 ring), 50.8 (CHCH2), 50.7 (NCH2CO). m/z
(ESMS, ESI+): 1,113 (100% [M + H]+), 1,135 (20% [M + Na]+).
tert-Butyl 2-(2-chloroacetamido)acetate
Glycine tert-butyl ester hydrochloride (6.3 g, 37.8 mmol) and potassium carbonate (15.7 g,
113.5 mmol) were dissolved in water (200 mL) and CH2Cl2 (200 mL) was added. The biphasic
reaction mixture was cooled to 273 K and a solution of chloroacetyl chloride (8.5 g, 75.6 mmol)
in CH2Cl2 (40 mL) was added dropwise. The reaction was stirred at 273 K for 30 min and then
allowed to warm to room temperature and was stirred for 1 h. The two layers were separated
and the organic layer was washed with 5% aqueous citric acid (2 × 40 mL) and water (2 × 40

J Biol Inorg Chem. Author manuscript; available in PMC 2009 October 9.
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mL) before drying (Na2SO4). The solvents were removed in vacuo to afford tert-butyl 2-(2chloroacetamido)acetate (7) as a colorless solid (7.8 g, 99%). Melting point 340.5-341 K. 1H
NMR (400 MHz, CDCl3, δ): 7.17 (1H, s br, NH), 4.11 (2H, s, CH2Cl), 4.00 (2H, d, 2JH–H =
4.0 Hz, NHCH2), 1.51 [9H, s, C(CH3)3]. 13C NMR (100 MHz, CDCl3, δ): 168.2 (CO2), 166.0
(NHCO), 82.5 [C(CH3)3], 42.2 (NHCH2CO), 42.0 (ClCH2), 27.8 [C(CH3)3]. νmax (cm−1):
3,245 (NH), 3,087, 2,975, 1,734 (C=O), 1,652 (C=O), 1,557, 1,540, 1,409, 1,365, 1,228, 1,160,
1,039. m/z (ESMS, ESI–): 206 (100%, [M – H]−); an appropriate chlorine isotope pattern was
observed. Anal. Found (Calcd for C8H14ClNO3): C, 46.1 (46.3); H, 6.8 (6.8); N, 6.7 (6.8).
1,7-Bis(benzyloxycarbonyl)-4,10-bis(tert-butylacetamidoacetate)-1,4,7,10tetraazacyclododecane

NIH-PA Author Manuscript

The chloroacetamide 7 (3.0 g, 14.4 mmol) and potassium carbonate (3.0 g, 21.7 mmol) were
added to a solution of the diprotected cyclen 8 (3.2 g, 7.2 mmol) in CH3CN (80 mL). The
reaction mixture was heated with stirring at 333 K for 3 days. After cooling to room
temperature, the reaction mixture was filtered and the solvents were removed under reduced
pressure. The oily residue was dissolved in diethyl ether (200 mL) and washed with water (2
× 50 mL), and dried (Na2SO4). The solvents were removed under vacuum and the oily residue
was purified by column chromatography over silica gel eluting with 5% CH3OH and 0.3%
NH4OH in CH2Cl2 to afford 1,7-bis (benzyloxycarbonyl)-4,10-bis(tert-butylacetamidoacetate)-1,4,7,10-tetraazacyclododecane (9) as a colorless solid (4.1 g, 73%). Rf =
0.33 (SiO2, 5% CH3OH, and 0.3% NH4OH in CH2Cl2). Melting point 334-335.5 K. 1H NMR
(270 MHz, CDCl3, δ): 7.29 (10H, m, Ar), 5.06 (4H, s, OCH2Ar), 3.78 (4H, s br, NHCH2CO),
3.42 (8H, s br, NCH2 ring), 3.17 (4H, s br, NCH2CO), 2.80 (8H, s br, NCH2 ring), 1.40 [18H,
s, C(CH3)3]. 13C NMR (68 MHz, CDCl3, δ): 171.3 (NHC=O), 168.9 (NCO2), 156.9 (NHC=O),
136.6 (Ar), 128.6 (Ar), 128.4 (Ar), 128.3 (Ar), 81.8 [C(CH3)3], 67.4 (OCH2Ar), 58.4 (NCH2
ring), 55.1 (NCH2CO), 48.9 (NCH2 ring), 41.6 (NHCH2CO), 28.1 (C(CH3)3). νmax (cm−1):
3,288 (NH), 2,974, 2,922, 2,811, 1,740 (C=O), 1,687 (C=O), 1,650 (C=O), 1,521, 1,456, 1,416,
1,366, 1,220, 1,151. m/z (MALDI/TOF): 783 (100% [M + H]+). Anal. Found (Calcd for
C40H58N6O10·0.2HCl): C, 60.6 (60.8); H, 7.3 (7.4); N, 10.4 (10.6).
1,7-Bis(tert-butyl acetamidoacetate)-1,4,7, 10-tetraazacyclododecane
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To a solution of the dicarbamate 9 (8.2 g, 10.5 mmol) in absolute ethanol (80 mL) was added
10% Pd on carbon (1.0 g). The mixture was placed on a Parr hydrogenation apparatus and
shaken under a hydrogen pressure of 40 psi for 3 days. The reaction mixture was then filtered
and the solvents were removed from the filtrate under reduced pressure toafford 1,7-bis(tertbutyl acetamidoacetate)-1,4,7,10-tetraazacyclododecane (10) as a colorless oil (5.2 g,
96%). 1H NMR (270 MHz, CDCl3, δ): 7.77 (2H, s br, NH), 3.83 (4H, d, 2JH–H = 4 Hz,
NHCH2CO), 3.17 (4H, s, NCH2CO), 2.69-2.64 (16H, m br, NCH2 ring), 1.30 [18H, s, C
(CH3)3]. 13C NMR (68 MHz, CDCl3, δ): 171.6 (CO2), 169.6 (CONH), 82.0 [C(CH3)3], 60.5
(NHCH2CO), 53.0 (NCH2 ring), 46.5 (NCH2 ring), 41.7 (NCH2CO), 28.1 [C(CH3)3] νmax
(cm−1): 3,288 (NH), 2,974, 2,915, 1,740 (C=O), 1,689 (C=O), 1,524, 1,454, 1,416, 1,366,
1,263, 1,152, 730. m/z (MALDI/TOF): 515 (100% [M + H]+).
1,7-Bis[2-(methylene benzyloxy ether)-tert-butyl acetate] acetamide-4,10-bis(tertbutylacetamidoacetate)-1,4,7,10-tetraazacyclododecane
Hünig’s base (3.53 g, 27.30 mmol) and the bromoacetamide 5 (3.4 g, 9.1 mmol) were added
to a solution of the diamide 10 (2.3 g, 4.6 mmol) in CH3CN (60 mL). The reaction mixture
was heated with stirring at 333 K for 3 days. After cooling to room temperature, the solvents
were removed under reduced pressure and the oily residue was taken up into diethyl ether (150
mL). The solution was filtered and the solvents were removed from the filtrate to afford 1,7bis[2-(methylene benzyloxy ether)-tert-butyl acetate] acetamide-4,10-bis(tert-butyl-
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acetamidoacetate)-1,4,7,10-tetraazacyclododecane (11) as a glassy solid, which was used for
the next step without further purification. Melting point 330-333 K. 1H NMR (400 MHz,
CDCl3, δ): 8.32 (2H, s br, NH), 7.45 (2H, s br, NH), 7.18 (10H, m, Ar), 4.49 (2H, m,
NCHCO2), 4.44 (2H, d aa′ system, 2JH–H = 12 Hz, OCH2Ar), 4.36 (2H, d aa′ system, 2JH–H =
12 Hz, OCH2Ar), 3.77 (8H, m, CHCH2O, NCH2CO2), 3.65 (4H, s br, NCH2CO), 3.43 (4H, s
br, NCH2CO), 2.45–3.20 (16H, br, NCH2 ring), 1.34 [18H, s, C(CH3)3], 1.32 [18H, s, C
(CH3)3]. 13C NMR (100 MHz, CDCl3, δ): 193.2 (CO2), 188.0 (CO2), 169.6 (NHC=O), 169.4
(NHC=O), 138.0 (Ar), 129.0 (Ar), 128.4 (Ar), 128.3 (Ar), 82.9 [C(CH3)3], 73.9 (OCH2Ar),
70.3 (CHCH2O), 62.5 (NCHCH2), 57.1 (NCH2CO), 53.7 (br, NCH2 ring), 42.3 (NCH2CO2),
28.6 [C(CH3)3], 28.5 [C(CH3)3]. νmax (cm−1): 2,974, 2,922, 2,828, 2,812, 1,739 (C=O), 1,670
(C=O), 1,517, 1,454, 1,392, 1,366, 1,222, 1,152, 1,104. m/z (MALDI/TOF): 1,097 (100%, [M
+ H+]).
1,7-Bis[2-(methylene benzyloxy ether)-acetic acid] acetamide-4,10-bis(acetamidoacetic
acid)-1,4,7,10-tetraazacyclododecane

NIH-PA Author Manuscript

The tert-butyl ester 11 (1.0 g; 0.9 mmol) was dissolved in CH2Cl2 (5 mL) and TFA (8 mL)
was added. The reaction mixture was stirred at 298 K for 12 h and the solvents were removed
under reduced pressure. The resulting oily residue was washed with diethyl ether (3 × 50 mL)
and dried under vacuum. The solid residue was dissolved in water (18 mL) and purified by
preparative reversed-phase high-performance liquid chromatography (HPLC) over a
Phenomenex Luna C-18(2) (250 mm × 50 mm) column on a Waters δ-prep HPLC system.
Absorbance was monitored at 205 and 254 nm. The system was eluted with water (0.1% TFA)
for 5 min and then with a linear gradient to 50% MeCN (0.1% TFA) and 50% water (0.1%
TFA) after 15 min and maintained isocratically for a further 10 min, at a flow rate of 100 mL
min−1. 1,7-Bis[2-(methylene benzyloxy ether)-acetic acid] acetamide-4,10-bis
(acetamidoacetic acid)-1,4,7,10-tetraazacyclododecane (2) was obtained as a colorless solid
(0.44 g, 68%). HPLC Rt = 17.8 min. Melting point 397-399 K. 1H NMR (400 MHz, ND3OD,
δ): 7.15 (10H, m, Ar), 4.39 (2H, m, NCHCO2), 4.38 (2H, d aa′ system, 2JH–H = 12 Hz,
OCH2Ar), 4.32 (2H, d aa′ system, 2JH–H = 12 Hz, OCH2Ar), 4.11–3.34 (16H, m, CHCH2O,
NCH2CO2, NCH2CO), 2.40–3.34 (16H, m br, NCH2 ring). 13C NMR (100 MHz, CDCl3, δ):
172.9 (CO2), 163.2 (NHC=O), 162.8 (NHC=O), 137.1 (Ar), 128.8 (Ar), 128.5 (Ar), 128.4 (Ar),
73.0 (OCH2Ar), 68.5 [CHCH2O], 55.1 (NCH2CO), 54.5 (NCHCH2), 53.2 (NCH2CO), 50.0
(br, NCH2 ring), 41.1 (NCH2CO2). νmax (cm−1): 3,318 (OH), 2,973, 2,839, 1,731 (C=O), 1,688
(C=O), 1,538, 1,505, 1,455, 1,194, 1,134. m/z (MALDI/TOF): 873 (100% [M + H]+). Anal.
Found (Calcd for C40H56N8O14·3CF3CO2H·H2O): C, 45.3 (44.8); H, 4.9 (5.0); N, 9.0 (9.1).
General procedure for the preparation of lanthanide(III) complexes

NIH-PA Author Manuscript

An aqueous lanthanide chloride solution (0.21 M, 614 µL) was added to a solution of ligand
3 (0.14 g, 0.13 mmol) in 50:50 water/methanol (15 mL, pH 6.0). The resulting solution was
stirred for 3 days at 333 K and the pH was maintained between 6 and 7 throughout by addition
of 1 N KOH. The absence of free Ln3+ (Eu or Gd) was verified by colorimetric assay using
xylenol orange (1 M AcONa/AcOH buffer, pH 5.3). The reaction mixture was allowed to cool
to room temperature and the solvents were removed by freeze-drying. Eu2 m/z (ESMS, ESI
+): 1,022 (100% [M – 2H]+); an appropriate isotope pattern was observed. Gd2 m/z (ESMS,
ESI+): 1,030 (100% [M – 2H]+); an appropriate isotope pattern was observed. Yb2 m/z (ESMS,
ESI+): 1,044 (100% [M – 2H]+); an appropriate isotope pattern was observed. Eu3: m/z (ESMS,
ESI+): 1,263 (100%, [M – 2H]+); an appropriate isotope pattern was observed. Gd3 m/z (ESMS,
ESI+): 632 (100% [M – H]2+); an appropriate isotope pattern was observed.
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A quantitative description of the NMR behavior of two or more exchanging pools of nuclei is
described by the Bloch equations modified for exchange [19]. For the simplest situation of two
exchanging pools A and B, it has been shown that the maximum reduction in the water signal
occurs when (1) the nuclei in pool B are completely saturated so that
intensity
and (2) there is no direct excitation of pool A nuclei by the B1 irradiation that excites B
nuclei. Condition 1 is met when B1 is sufficiently large. Condition 2 is met when the relative
difference in resonance frequency of the two pools (Δω) is very large so that Δω/ω1 ≫ 1. Under
these conditions, the steady-state solution of the Bloch equations gives

(1)

where c is the concentration of the PARACEST agent and q is the number of bound water
molecules per PARACEST complex; τa is the residence lifetime in pool A, which is related,
through the relative concentration of the two pools, to τM, the residence lifetime in pool B; and
T1a is spinlattice relaxation time of bulk water.
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CEST images were acquired using a 200-MHz (1H) Varian Inova scanner. Spin-echo images
of two phantoms each containing 20 mM solutions of Eu2, one with and one without 5%
albumin, were acquired using a 6-s presaturation pulse applied off-resonance (−54 ppm) and
on-resonance (54 ppm), respectively, for each phantom. The percentage CEST enhancement
map, E, was computed from these images, where E = 100 × (Soff − Son)/Soff, using MATLAB
image processing software.

Results and discussion
Synthesis
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The synthetic routes to ligands 2 and 3 are outlined in Scheme 1. O-Benzyl-L-serine was
neutralized with sodium hydroxide and reacted with bromoacetyl bromide in a biphasic
reaction using potassium carbonate as a base. The carboxylate of the resulting bromoacetamide
4 was protected as a tert-butyl ester using tert-butyl trichloroace-timidate and BF3·OEt.
Although the yields for preparing derivatives of 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA) where the O-benzyl substituent is in the α-position of the acetate side
arms was reportedly low [20,21], alkylation of cyclen with 4 equiv of 5 in acetonitrile using
Hünig’s base at 328 K afforded the protected ligand 6 in 93% yield. Ligand 6 was then
deprotected using TFA to afford 3 in 25% overall yield from O-benzyl serine.
The trans-O-benzyl serine substituted ligand 2 was prepared by first preparing
bisbenzylcarbamate-protected cyclen from a well-established procedure using benzyl
chloroformate [18]. The tert-butyl ester of glycine was reacted with chloroacetyl chloride in a
biphasic reaction using potassium carbonate as a base to afford the chloroacetamide 7. This
was reacted with 8 using standard alkylating conditions to give 9 and the carbamate protecting
groups were then removed by catalytic hydrogenolysis over palladium on carbon to afford the
bisamide 10 in 96% yield. 10 was then alkylated with 5 in acetonitrile using Hünig’s base to
give the tetra-tert-butyl ester 11. Subsequent deprotection using TFA afforded 2 in 48% overall
yield from compound 8.
Lanthanide complexes of 2 and 3 were prepared by mixing equimolar quantities of the ligand
and the appropriate lanthanide chloride in a water/methanol solution at 333 K. The isolated
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yields of the complexes of 3 were lower than usual (approximately 30%), the result of the poor
solubility of ligand 3 in water. However, the resulting lanthanide complexes of 3 were found
to be more soluble in water than the previously reported LnDOTA–(BOM)4 complexes (where
BOM is benzyloxymethyl ether) [20,21].
Binding studies with human serum albumin
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Human serum albumin (HSA) is known to bind a variety of hydrophobic drugs in one of two
major binding domains, referred to as site I and site II [22,23]. A variety of fluorescence
methods have been developed to evaluate the binding sites and association constants of drugs
with HSA. Site I is the primary binding site for drugs like warfarin and various phenylbutazone
analogs, whereas diazepam and ibuprofen bind primarily at site II [24]. Warfarin itself has
fluorescence properties (λem = 320 nm) that allow it to be used to assay binding at site I, whereas
dansylsarcosine (λem = 360 nm) is frequently used as a fluorescent probe for site II [25]. Neither
Gd2 nor Gd3 fluoresces at those wavelengths. Consequently, the ability of Gd2 and Gd3 to
displace either of the fluorescent probes, warfarin or dansylsarcosine, from HSA was
investigated by monitoring the changes in fluorescence with added Gd2 or Gd3. Full details
of this procedure have previously been reported by Caravan et al. [25]. The fluorescence
emission intensity of these probes is higher when they are bound to HSA and consequently
their emission intensity decreases when they are displaced from their normal binding sites by
other compounds. The emission intensity of dansylsarcosine was found to fall after addition
of either Gd2 or Gd3 to a solution containing an equal concentration of dansylsar-cosine (5
µM) and HSA (5 µM) at 298 K and pH 7.4 (Fig. 1). In contrast, little or no change in
fluorescence intensity was observed when either Gd2 or Gd3 was added to a sample of HSA
(5 µM) containing 1 equiv of warfarin (5 µM). This indicates that Gd2 and Gd3 both bind at
a site II subdomain of HSA but have no, or only weak, binding affinity for site I. The data
obtained for the displacement of dansylsarcosine from HSA by both Gd2 and Gd3 (Fig. 1)
were fitted to an inhibition binding model (Eq. 2, Eq. 3).

(2)

where

(3)
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Here [FP]bound and [FP]t are concentrations of the fluorescent probe bound to HSA and the
total concentration of fluorescent probe, respectively, [HSA]t is the total concentration of HSA
and [GdL]free is the concentration of unbound gadolinium complex. KA is the association
constant of the fluoresecent probe with HSA,
is the apparent dissociation constant of the
fluorescent probe from HSA in the presence of Gd2 and Gd3, and 1/KI is the site-specific
association constant of the gadolinium complexes with HSA. The value of KA for HSA and
dansylsarcosine in phosphate-buffered saline (PBS) (1.45 × 106 M−1) was taken from the
literature [26]. Fitting the titration curves obtained by displacement of dansylsarcosine with
Gd2 and Gd3 (Fig. 1) to Eq. 2 and Eq. 3 gave 1/KI values of 3.14 and 1.04 × 104 M−1 for the
binding of Gd2 and Gd3 at site II, respectively. These association constants are considerably
higher (40-fold) than those determined for the binding of GdEOB-DTPA is (where EOB-DTPA
(2-ethoxybenzyl-diethylenetriamine pentaacetic acid) with HSA [16], a lipophilic
hepatobiliary targeted CA, and are comparable with that of the high-affinity HSA binding blood
pool agent MS-325 [25].
J Biol Inorg Chem. Author manuscript; available in PMC 2009 October 9.
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The binding of Gd2 and Gd3 to HSA was further verified by water proton relaxation titrations.
The relaxivities of Gd2 (1.9 mM−1 s−1) and Gd3 (2.2 mM−1 s−1) (20 MHz, 298 K) resemble
values reported for outer-sphere-only complexes (q = 0) [27] more closely than those of
gadolinium complexes containing a single, inner-sphere coordinated water molecule (q = 1)
[28]. However, these values are also consistent with complexes that have a single, inner-sphere
water molecule that is in slow water exchange with bulk water (also validated in CEST spectra;
see later). Upon addition of HSA, the relaxivities of Gd2 and Gd3 gradually increased with
increasing HSA concentration to values approaching 4.6 and 5.9 mM−1 s−1 at 2 mM HSA,
respectively, consistent with binding of the complexes to HSA (Fig. 2). This increase in
relaxivity is small compared with that for other HSA-binding systems that exhibit more rapid
water exchange [21,25,29], also indicating the water exchange kinetics in both Gd2 and Gd3
are slow.
CEST studies
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PARACEST agents are commonly characterized by selectively presaturating an aqueous
sample of the agent in incremental steps over a range of frequencies and plotting the remaining
steady-state bulk water signal, Ms/M0, versus saturation frequency. This was originally referred
to as a Z-spectrum [30] and more recently as a CEST spectrum [31]. Figure 3 shows plots of
Ms/M0 versus saturation frequency for 40 mM Eu2 and 20 mM Eu3 both collected in pure
water as solvent at 298 K. The peak at 0 ppm represents direct saturation of bulk water, while
the peak centered near 54 ppm reflects the chemical exchange between a Eu3+-bound water
molecule and bulk solvent. The hyperfine shift and water exchange properties of EuDOTA
tetraamide complexes typically have properties favorable for CEST with a peak arising from
the slowly exchanging water molecule near 50 ppm. An approximately 35% decrease in bulk
water signal intensity was observed for the Eu3 sample, while the more highly concentrated
Eu2 sample resulted in a 64% decrease in bulk water signal intensity under identical conditions.
Eu2 proved to be more soluble in water (approximately 3 M) than Eu3.
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In contrast to these EuDOTA tetraamide complexes, a water-exchange CEST peak is typically
not seen for the corresponding Yb3+ complexes. This is believed to be the result of water
exchange kinetics that lie outside the permissible range for CEST, viz., water exchange is too
fast [32,33]. Nonetheless, a CEST effect arising from the amide protons of these ytterbium
complexes can usually be observed [4,12] and so the CEST spectrum of Yb2 at 25 mM was
recorded. Two different irradiation powers and durations were employed in the acquisition of
these CEST spectra. Two peaks were detected near −18 and −56 ppm in the CEST spectrum
when a relatively high-power (26-µT) presaturation pulse was applied for 1 s. These were
assigned to the exchanging –NH amide protons in the complex; the peak at −18 ppm is at a
shift similar to those reported for other Yb3+ complexes by Aime et al. [11] and Zhang et al.
[12]. The peak at −56 ppm is unusually highly shifted; the largest shift previously reported was
that observed by Aime et al. [13] and was −29 ppm. When a lower-power (6.5-µT) presaturation
pulse was applied for 4 s, a broad (relatively fast exchanging) but detectable CEST peak was
observed near 230 ppm. This peak can only be assigned to an exchanging inner-sphere water
molecule on the Yb3+. Although a Yb3+-bound water resonance has not been detected
previously by 1H NMR, presumably owing to rapid water exchange, the chemical shift position
for a Yb3+-bound water molecule for ligand systems such as these was previously predicted
to be near 200 ppm on the basis of chemical shift comparisons with other ligand resonances
[32]. The low irradiation power and long duration used to record this spectrum were critical to
the observation of this bound water molecule because at higher powers the rapid exchange
kinetics and off-resonance direct saturation led to a coalescence of the bulk and bound water
peaks, obscuring the CEST peak from the bound water. Although the CEST effect from the
Yb3+-bound water molecule in Yb2 is relatively weak, this system does offer the possibility
of using the CEST ratio (H2O vs. NH) [10] as a direct indicator of sample pH (Fig. 4).
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Many of the gadolinium complexes designed to bind to serum albumin have been reported to
exhibit a change in their water exchange kinetics upon binding to the protein [17,25,34].
Usually the result is a deceleration of water exchange. Given the sensitivity of CEST to changes
in water exchange rates [19,35] it is critical that binding of the PARACEST agents Ln2 and
Ln3 to HSA does not result in adverse water exchange kinetics. Accordingly, the CEST spectra
of Eu2, Yb2, Tm2, and Eu3 were recorded in PBS (pH 7.4) in the presence and absence of
HSA. The change in the CEST properties of the chelate upon binding to HSA were only
minimal as exemplified by the spectra of Eu2 with and without HSA (Fig. 5). The CEST spectra
were recorded under conditions designed to ensure that essentially all of the Eu2 was bound
to HSA; the concentrations of both protein and PARACEST agent were 0.75 mM in a PBS
buffer and for comparative purposes a second CEST spectrum was acquired in the absence of
HSA. The two spectra resemble one another closely, although the width of the direct saturation
peak at 0 ppm is greater in the presence of the protein, a result of proton-exchange events
occurring between the protein and bulk water in addition to an increase in sample viscosity
that shortens T2. The similarity in the CEST peaks arising from the coordinated water molecule
in the presence and absence of HSA indicates that the water exchange kinetics of the complex
are not negatively impacted by the protein binding event. Color-coded CEST images of
phantoms collected in the absence and presence of HSA (Fig. 6) demonstrate nicely that the
images are relatively insensitive to the presence of protein.
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The CEST spectra of Eu2 shown in Fig. 5 were fitted to the Bloch equations modified for CEST
[19]. This fitting procedure is hampered by the necessarily low concentration of PARACEST
agent that results in small CEST effects, and the presence of the protein, which broadens the
direct saturation peak. The latter is the most problematic during the fitting procedure because
account must be taken for the additional OH, NH, and water molecules that are associated with
the protein. The CEST spectrum of Eu2 (Fig. 5, blue spectrum) was fitted to a two-pool (bulk
and coordinated water) and three-pool (bulk and coordinated water and amide protons) model;
the water residence lifetime (τM) obtained from this fitting was 1.0 ± 0.1 ms. This corresponds
to a much slower rate of water exchange than was reported for the parent complex Eu12 (τM
= 0.38 ms), consistent with the hypothesis put forward by Aime et al. [36] that bulkier and
more hydrophobic amide substituents lead to slower water exchange rates. In fitting the CEST
spectrum of Eu2 bound to HSA (Fig. 5, red spectrum) two approaches were taken. For model
1, no steps were taken to account for the presence of exchanging protons associated with the
protein and allowed extremely short bulk water T2 values to account for the increased linewidth
of the bulk solvent. For model 2, a large number of exchanging protons that could exchange
with bulk water but not the agent were added; the relaxation time, shift, and magnitude of this
“protein” pool were allowed considerable freedom during the fitting procedure. The fitting of
this spectrum is, as a result, highly qualitative; however, irrespective of the approach taken in
fitting the data, the water residence lifetime (τM) of Eu2 was found to decrease by a factor of
approximately 2 upon binding to HSA. The water residence lifetime (τM) of Eu2 bound to HSA
was estimated at 0.44 ms from model 1 and 0.66 ms from model 2. This acceleration of the
water exchange rate is in marked contrast to the deceleration in water exchange rate observed
in many other systems [17,25,34] but is not without precedent; complexes entrapped in the
protein apoferritin have been reported to undergo acceleration of water exchange [37,38].

Conclusions
Water exchange in Gd3+-based CAs plays a part in determining the relaxation efficiency or
relaxivity of a complex, particularly when the complex experiences slower rotation such as
when it is bound to a macromolecule. The bound-water lifetime in octadentate complexes of
Gd3+, such as those formed with simple polyamino–polycarboxylate ligands like DTPA or
DOTA, is typically 200–300 ns, but even this can limit the relaxivity of such complexes when
they are targeted to a biological macromolecule. The optimal bound-water lifetime has been
J Biol Inorg Chem. Author manuscript; available in PMC 2009 October 9.
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estimated at 20–30 ns. CEST-based CAs are also sensitive to water exchange even in the
absence of a macromolecular binding. If water exchange is too fast, the chemical shift of the
exchanging water molecule averages with that of bulk water and CEST cannot be initiated, but
if water exchange is too slow, the presaturated spins fully relax before CEST can occur. Hence,
there is an optimal water exchange rate for any CEST agent and that optimal rate can be further
influenced by the chemical environment of the agent. For example, acidic or basic
environments have been shown to catalyze proton exchange between a slowly exchanging
Ln3+-bound water molecule and bulk water; this effect would be likely to alter the CEST
properties of the agent [28], [41]. It has been reported that water exchange in Gd3+-based CAs
slows when such complexes are bound to albumin. For example, the bound-water lifetime in
GdDTPA(BOM)3, which also binds to HSA through benzyloxyether groups, increases by
approximately 50% when this complex binds noncovalently to HSA [16]. The effect is even
more dramatic in GdPCTP (where PCTP is 3,6,10,16-tetraazabicyclo[10.3.1]hexadeca-1(16),
12,14-triene-N′,N″,N′″-trimethylenephosphonic acid) [13], where the bound-water lifetime
increases from approximately 8 to 290 ns (approximately 30-fold slower) when this q = 1
complex binds to HSA [40]. Such a substantial change in water exchange would have a
profound influence on the CEST properties of similar albumin-binding PARACEST agents.
In the case of Eu2, the bound-water lifetime determined from fitting CEST spectra indicates
that water exchange accelerates (by a factor of approximately 2) when this complex binds with
HSA. Given the slow water exchange rate in this complex when it is not bound to HSA, the
change in water exchange rate was found to have little influence on the CEST properties of the
agent upon binding to HSA. The slow water exchange kinetics of these complexes mean that
a CEST effect arising from the protons of a water molecule coordinated to Yb3+ can be observed
for the first time.
In summary, fluorescence displacement experiments showed that both Gd2 and Gd3 bind
reversibly at site II of HSA and this results in a slowing of water exchange by about two fold.
The relatively small increase in water proton relaxivity that was observed upon addition of
HSA to either Gd2 or Gd3 is also consistent with slow water exchange systems both in the
absence and in the presence of HSA. The fact that HSA has a high binding affinity for these
PARACEST agents and that CEST is not quenched by protein binding make them potentially
useful as vasculature imaging agents although improvements in sensitivity may be required
prior to in vivo application.
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Fig. 1.

The inhibition of dansylsarcosine binding to human serum albumin (HSA) by Gd2 (circles)
and Gd3 (diamonds)
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Fig. 2.

Binding of the complexes Gd2 (circles) and Gd3 (diamonds) to HSA has the effect of increasing
the longitudinal relaxivity (r1) of each complex. Titrations were performed at 20 MHz, 298 K,
in N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid buffer, pH 7.4
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Fig. 3.

Chemical exchange saturation transfer (CEST) spectra, plotting the solvent water signal
intensity (expressed as a percentage of its initial intensity) against presaturation frequency, for
a 40 mM aqueous solution of Eu2 (top) and a 20 mM aqueous solution of Eu3 (bottom) at 298
K, irradiation time 2 s, B1 = 26 µT
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Fig. 4.

CEST spectra of a 25 mM solution of Yb2 recorded at 500 MHz, pH 7.4, and 298 K. On the
left is shown the downfield region of the spectrum recorded with an irradiation time of 4 s,
B1 = 6.5 µT; a small CEST peak arising from the coordinated water molecule is clearly visible.
On the right is shown the upfield region for an irradiation time of 1 s, B1 = 26 µT; CEST peaks
arising from the amide NH protons can be seen
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Fig. 5.

The CEST spectra of 0.75 mM Eu2 in phosphate-buffered saline (PBS) recorded in the absence
(blue) and presence (red) of 0.75 mM HSA. B0 = 400 MHz, B1 = 19 µT, irradiation time 6 s,
298 K
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Fig. 6.

Images of 20 mM solutions of Eu2 in the absence and presence of 5% HSA. Left (a, d),
center (b, e), and right (c, f) columns represent the off-resonance (−54 ppm), on-resonance (54
ppm), and the percentage CEST enhancement maps, respectively. Samples in the top row
contained 20 mM Eu2 in PBS, while samples in the bottom row contained in addition 5% HSA
(Buminate®). Each image was collected using a standard spin-echo sequence with a 6-s
presaturation pulse applied at the indicated offset
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Scheme 1.

The synthetic route to ligands 2 and 3. Reagents and conditions: i BrCH2COBr/K2CO3/NaOH/
273 K; ii tert-butyl trichloroacetimidate/BF3·OEt/tetrahydrofuran/273 K; iii cyclen/iPr2NEt/
MeCN/328 K; iv trifluoroacetic acid (TFA); v ClCH2COCl/K2CO3/H2O/CH2Cl2/273 K; vi
K2CO3/MeCN/333 K; vii H2/Pd on C; viii iPr2NEt/MeCN/333 K; ix TFA
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Structure 1.
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